Daiichi Sankyo (OTCMKTS:DSNKY) Sees Unusually-High Trading Volume - Here's What Happened

Daiichi Sankyo logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Daiichi Sankyo shares traded unusually actively: 804,812 shares changed hands, 164% above average volume, while the stock rose to $18.80 from its prior close of $18.15.
  • Recent quarterly results beat expectations: EPS was $0.29 versus the $0.21 consensus, and revenue of $3.77 billion exceeded the $3.58 billion estimate.
  • Analyst sentiment is cautious: Jefferies downgraded the shares to Hold and Zacks Research to Strong Sell, giving the stock a MarketBeat consensus rating of “Reduce.”
  • Five stocks we like better than Daiichi Sankyo.

Shares of Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY - Get Free Report) saw strong trading volume on Wednesday. 804,812 shares were traded during mid-day trading, an increase of 164% from the average daily volume of 304,809 shares. The stock last traded at $18.80 and had previously closed at $18.15.

Analyst Upgrades and Downgrades

DSNKY has been the subject of a number of recent analyst reports. Jefferies Financial Group lowered shares of Daiichi Sankyo from a "buy" rating to a "hold" rating in a report on Thursday, July 30th. Zacks Research lowered shares of Daiichi Sankyo from a "hold" rating to a "strong sell" rating in a report on Tuesday, October 20th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Reduce".

View Our Latest Report on DSNKY

Daiichi Sankyo Stock Performance

The company's 50-day moving average price is $17.77 and its 200 day moving average price is $17.63. The stock has a market capitalization of $35.04 billion, a PE ratio of 19.19, a PEG ratio of 2.08 and a beta of -0.10. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.96 and a current ratio of 2.92.

Daiichi Sankyo (OTCMKTS:DSNKY - Get Free Report) last released its quarterly earnings results on Friday, October 30th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.21 by $0.08. Daiichi Sankyo had a net margin of 12.13% and a return on equity of 16.31%. The company had revenue of $3.77 billion during the quarter, compared to the consensus estimate of $3.58 billion. On average, equities research analysts expect that Daiichi Sankyo Co., Ltd. - Sponsored ADR will post 0.87 earnings per share for the current fiscal year.

Daiichi Sankyo Company Profile

(Get Free Report)

Daiichi Sankyo Co, Ltd. is a Japan-based global pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company focuses primarily on oncology, with additional activities in areas such as cardiovascular disease, rare diseases and other specialty therapies. Its products are marketed in Japan and internationally through subsidiaries, partnerships and licensing agreements.

Daiichi Sankyo is particularly known for its antibody-drug conjugate technology, which is designed to deliver cancer-killing agents more selectively to tumor cells.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Daiichi Sankyo Right Now?

Before you consider Daiichi Sankyo, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Daiichi Sankyo wasn't on the list.

While Daiichi Sankyo currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines